Human MHCG/HLA-G(Major Histocompatibility Complex Class Ⅰ G) ELISA Kit
中文名称：人Ⅰ类主要组织相容性复合体G(MHCG/HLA-G)酶联免疫吸附测定试剂盒
Price:
- 反应性： Human
- 检测范围： 0.63-40 ng/mL
- 灵敏度： 0.38 ng/mL
| 产品应用 | ELISA |
| 检测原理 | 本试剂盒采用双抗体夹心ELISA法。用抗人MHCG/HLA-G抗体包被于酶标板上，实验时样品（或标准品）中的人MHCG/HLA-G会与包被抗体结合。后依次加入生物素化的抗人MHCG/HLA-G抗体和辣根过氧化物酶标记的亲和素，抗人MHCG/HLA-G抗体与结合在包被抗体上的人MHCG/HLA-G结合，生物素与亲和素特异性结合而形成免疫复合物，游离的成分被洗去。加入显色底物(TMB)，TMB在辣根过氧化物酶的催化下呈现蓝色，加终止液后变成黄色。用酶标仪在450 nm波长处测OD值，MHCG/HLA-G浓度与OD450值之间呈正比，通过绘制标准曲线计算出样品中MHCG/HLA-G的浓度。 |
| 反应类型 | Sandwich-ELISA |
| 规格 |
96 T
/ 48 T
/ 96 T × 5
|
| 反应时间 | 3 h 30 min |
| 反应性 | Human |
| 检测方法 | 比色法;ELISA;夹心法 |
| 检测范围 | 0.63-40 ng/mL |
| 灵敏度 | 0.38 ng/mL |
| 样本体积 | 100 μL |
| 样本类型 | 血清、血浆或其他生物体液 |
| 特异性 | 可检测样本中的人MHCG/HLA-G，且与其它类似物无明显交叉反应 |
| 精密度 | 板内，板间变异系数均<10% |
| 回收率 | 80%-120% |
| 储存条件 | 2-8℃ |
| 有效期 | 12个月 |
| 数据处理 |
-
The implication of serum HLA-G in angiogenesis of multiple myeloma
IF: 6.000 -
Immune-checkpoint HLA-G gene polymorphisms, 3’-UTR types and their association with hepatocellular carcinoma and treatment response in Indian population
IF: 5.700Journal： Frontiers in Immunology (2024)Reactivity：HumanSample Type：sera -
HLA-G Expression/Secretion and T-Cell Cytotoxicity in Missed Abortion in Comparison to Normal Pregnancy
IF: 5.600Journal： INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2024)PMID：38473890Reactivity：HumanSample Type：serum -
How the Soluble Human Leukocyte Antigen-G levels in Amniotic Fluid and Maternal Serum Correlate with the Feto-Placental Growth in Uncomplicated Pregnancies
IF: 3.800Journal： Bioengineering-Basel (2024)Reactivity：HumanSample Type：serum,amniotic fluid -
Impact of Vitamin D deficiency on immunological and metabolic responses in women with recurrent pregnancy loss: focus on VDBP/HLA-G1/CTLA-4/ENTPD1/adenosine-fetal-maternal conflict crosstalk
IF: 2.800Journal： BMC Pregnancy and Childbirth (2024)Reactivity：HumanSample Type：Serum -
Predictive Capabilities of Human Leukocyte Antigen-G and Galectin-13 Levels in the Amniotic Fluid and Maternal Blood for the Pregnancy Outcome
IF: 2.600 -
Soluble HLA-G (sHLA-G) measurement might be useful as an early diagnostic biomarker and screening test for gastric cancer
IF: 4.600 -
Determination of soluble HLA-G serum levels in patients with adenomyosis and uterine fibroids before and after surgery
IF: 2.700 -
Downregulated cytotoxic CD8+ T-cell identifies with the NKG2A-soluble HLA-E axis as a predictive biomarker and potential therapeutic target in keloids
IF: 22.096 -
The Potential of Soluble Human Leukocyte Antigen Molecules for Early Cancer Detection and Therapeutic Vaccine Design
IF: 4.086
实验操作视频
